Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

 
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
 

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
 
How to report

You can send the case reports using the following tools:
 
  1. For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
 
  1. The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones
 
  1. Scan the QR Code by pressing the link
  2. Click the three dots in the top-right corner
  3. Choose Install app
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app
 
How to Download on Apple IOS Phones
 
  1. Scan the QR Code by pressing the link
  2. Click on the share button
  3. Add VigiMobile to the home screen
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows
  1. Press on the link
  2. Install from the Browser menu
  3. VigiMobile e-Form/e-Reporting e-Form is now installed 
 
Scan QR Codes to Report:
  1. ADRs Following Medication Use
  1. AEFIs Following Vaccine Use
Or use the following link: LNPVP: e-Reporting eForm Or use the following link: LNPVP: VigiMobile eForm
 
  1. Direct Contact with the Lebanese National Pharmacovigilance Program:
You may contact the Lebanese National Pharmacovigilance Program through:
  • Email Address:
  • Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254   
 
  1.  For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.
 
As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-
 
    ...
    83
    ...
ATC Name B/G Ingredients Dosage Form Price
J05AF10 ENTRILIV G Entecavir - 1mg 1mg Tablet, film coated 19,165,898 L.L
J05AF10 ENTECAVIR BIOGARAN G Entecavir - 1mg 1mg Tablet, coated 19,080,319 L.L
J05AF10 ENTECAVIR ARROW G Entecavir - 1mg 1mg Tablet, coated 18,701,506 L.L
J05AF10 AVIRAVIR G Entecavir monohydrate - 1mg 1mg Tablet, film coated 31,285,380 L.L
J05AF07 TENVOR G Tenofovir disoproxil fumarate - 300mg 300mg Tablet, film coated 3,753,352 L.L
J05AF07 TENOREAD G Tenofovir disoproxil fumarate - 300mg 300mg Tablet, film coated 7,129,777 L.L
J05AF07 TENOFOVIR DISOPROXIL BIOGARAN G Tenofovir disoproxil - 245mg 245mg Tablet, film coated 9,747,613 L.L
J05AF07 TENOFOVIR DISOPROXIL ARROW G Tenofovir disoproxil - 245mg 245mg Tablet, film coated 9,747,613 L.L
J05AF07 VIREAD B Tenofovir disoproxil - 245mg 245mg Tablet, film coated 15,716,313 L.L
J05AF05 LAMIVUDINE ARROW G Lamivudine - 300mg 300mg Tablet, coated 7,850,907 L.L
J05AF05 VICONDINE G Lamivudine - 150mg 150mg Tablet, film coated 3,573,725 L.L
J05AF05 LAMIVUDINE ARROW G Lamivudine - 150mg 150mg Tablet, coated, scored 7,850,907 L.L
J05AF01 REVODINE G Zidovudine - 300mg 300mg Tablet, film coated 7,771,552 L.L
J05AB16 FLEXIVIR G Remdesivir - 50mg 50mg Injectable lyophilised powder for solution 4,837,833 L.L
J05AB14 VALGANCICLOVIR ARROW G Valganciclovir (HCl) - 450mg 450mg Tablet, coated 44,309,215 L.L
J05AB14 VAGLONAX G Valganciclovir (HCl) - 450mg 450mg Tablet, film coated 49,858,549 L.L
J05AB14 VALCYTE B Valganciclovir (HCl) - 450mg 450mg Tablet, film coated 63,612,039 L.L
J05AB11 VALCYK BENTA G Valaciclovir - 500mg 500mg Tablet, film coated 945,809 L.L
J05AB11 VALCYK BENTA G Valaciclovir - 500mg 500mg Tablet, film coated 4,318,214 L.L
J05AB11 VALACICLOVIR ARROW G Valaciclovir - 500mg 500mg Tablet, film coated, breakable 2,889,261 L.L
J05AB11 VALACICLOVIR ARROW G Valaciclovir - 500mg 500mg Tablet, film coated, breakable 753,896 L.L
J05AB11 VALTREX B Valaciclovir - 500mg 500mg Tablet, film coated 4,481,715 L.L
J05AB11 VALTREX B Valaciclovir - 500mg 500mg Tablet, film coated 1,169,143 L.L
J05AB06 CYMEVENE B Ganciclovir (sodium) - 500mg 500mg Injectable solution 1,726,838 L.L
J05AB01 VICLORIX 800 G Aciclovir - 800mg 800mg Tablet 4,321,797 L.L
J05AB01 VICLORIX 400 G Aciclovir - 400mg 400mg Tablet 3,589,851 L.L
J05AB01 CYCLOVEX G Aciclovir - 400mg 400mg Tablet, scored 2,687,685 L.L
J05AB01 CYCLOVEX G Aciclovir - 200mg 200mg Tablet, scored 1,164,664 L.L
J05AB01 ACTI-VIR G Aciclovir - 200mg 200mg Tablet, scored 1,039,238 L.L
J05AB01 ZOVIRAX B Aciclovir - 200mg/5ml 200mg/5ml Suspension 487,815 L.L
    ...
    83
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025